Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
46.61
+2.37 (5.36%)
At close: May 12, 2025, 4:00 PM
46.61
0.00 (0.00%)
After-hours: May 12, 2025, 4:39 PM EDT
Disc Medicine Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Disc Medicine stock have an average target of 93.89, with a low estimate of 57 and a high estimate of 132. The average target predicts an increase of 101.44% from the current stock price of 46.61.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Disc Medicine stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 6 | 6 | 6 | 7 | 7 | 6 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $112 → $120 | Buy | Maintains | $112 → $120 | +157.46% | May 12, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $99 → $132 | Buy | Maintains | $99 → $132 | +183.20% | Mar 18, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $85 | Buy | Initiates | $85 | +82.36% | Mar 7, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $73 → $75 | Buy | Maintains | $73 → $75 | +60.91% | Mar 3, 2025 |
| Stifel | Stifel | Strong Buy Maintains $90 → $94 | Strong Buy | Maintains | $90 → $94 | +101.67% | Jan 24, 2025 |
Financial Forecast
Revenue This Year
n/a
from 447.96M
Revenue Next Year
n/a
EPS This Year
-5.01
from -3.96
EPS Next Year
-5.03
from -5.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 57.8M | 195.3M | ||
| Avg | n/a | 30.0M | 116.7M | ||
| Low | n/a | n/a | 9.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 549.9% | ||
| Avg | - | - | 288.5% | ||
| Low | - | - | -67.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.88 | -3.74 | -1.43 | ||
| Avg | -5.01 | -5.03 | -4.24 | ||
| Low | -5.82 | -7.55 | -8.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.